- Home
- HUDI vs ANTX Comparison
HUDI vs ANTX Comparison
Compare HUDI & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUDI
- ANTX
- Stock Information
- Founded
- HUDI 1998
- ANTX 2017
- Country
- HUDI China
- ANTX United States
- Employees
- HUDI N/A
- ANTX 36
- Industry
- HUDI Steel/Iron Ore
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- HUDI Industrials
- ANTX Health Care
- Exchange
- HUDI Nasdaq
- ANTX Nasdaq
- Market Cap
- HUDI 28.4M
- ANTX 40.0M
- IPO Year
- HUDI 2021
- ANTX 2022
- Fundamental
- Price
- HUDI $1.95
- ANTX $1.34
- Analyst Decision
- HUDI
- ANTX Hold
- Analyst Count
- HUDI 0
- ANTX 5
- Target Price
- HUDI N/A
- ANTX $3.50
- AVG Volume (30 Days)
- HUDI 16.7K
- ANTX 1.0M
- Earning Date
- HUDI 08-06-2024
- ANTX 11-13-2024
- Dividend Yield
- HUDI N/A
- ANTX N/A
- EPS Growth
- HUDI N/A
- ANTX N/A
- EPS
- HUDI 0.18
- ANTX N/A
- Revenue
- HUDI $83,462,634.00
- ANTX N/A
- Revenue This Year
- HUDI N/A
- ANTX N/A
- Revenue Next Year
- HUDI N/A
- ANTX N/A
- P/E Ratio
- HUDI $10.59
- ANTX N/A
- Revenue Growth
- HUDI 7.65
- ANTX N/A
- 52 Week Low
- HUDI $1.88
- ANTX $0.87
- 52 Week High
- HUDI $4.25
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- HUDI 41.70
- ANTX 72.02
- Support Level
- HUDI $1.93
- ANTX $0.98
- Resistance Level
- HUDI $2.09
- ANTX $1.46
- Average True Range (ATR)
- HUDI 0.08
- ANTX 0.08
- MACD
- HUDI 0.01
- ANTX 0.03
- Stochastic Oscillator
- HUDI 26.32
- ANTX 75.26
About HUDI Huadi International Group Co. Ltd.
Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Products are exported to the United States, Mexico, Thailand, Australia, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.